(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
28 August 2025 (28.08.2025)

WIPO | PCT

(10) International Publication Number
WO 2025/176614 A1

(51) International Patent Classification:
A61P 35/00 (2006.01) *C07K 16/30* (2006.01)
A61K 51/10 (2006.01) *C07K 16/44* (2006.01)

(21) International Application Number:
PCT/EP2025/054241

(22) International Filing Date:
18 February 2025 (18.02.2025)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
24158512.4 20 February 2024 (20.02.2024) EP

(71) Applicant *(for all designated States except US)*: **F. HOFFMANN-LA ROCHE AG** [CH/CH]; Grenzacherstrasse 124, 4070 Basel (CH).

(71) Applicant *(for US only)*: **HOFFMANN-LA ROCHE INC.** [US/US]; Overlook at Great Notch, 150 Clove Road, 8th Floor, Suite 8 - Legal Department, Little Falls, New Jersey 07424 (US).

(72) Inventors: **BUJOTZEK, Alexander Christian**; c/o Roche Diagnostics GmbH, Nonnenwald 2, 82377 Penzberg (DE). **FROST, Sofia Helena Linnea**; c/o Roche Products Limited, Hexagon Place, 6 Falcon Way, Shire Park, Welwyn Garden City AL7 1TW (GB). **HAAS, Alexander Klaus**; c/o Roche Diagnostics GmbH, Nonnenwald 2, 82377 Penzberg (DE). **IMHOF-JUNG, Sabine**; c/o Roche Diagnostics GmbH, Nonnenwald 2, 82377 Penzberg (DE). **NIKOLOV, Miroslav Albertov**; c/o Roche Diagnostics GmbH, Nonnenwald 2, 82377 Penzberg (DE).

(74) Agent: **BEYERMANN, Jochen Carl**; F. Hoffmann-La Roche AG, Patent Department, Grenzacherstrasse 124, 4070 Basel (CH).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UY, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ,

(54) Title: NOVEL PRE-TARGETING ANTIBODIES AND USES THEREOF

Fig. 13A



Target Binder	Effector		Protein	LC	HC	FusionHC
CH1A1A	Dotam	VL	P1AI0446	D1AD3421	D1AC4023	D1AK6882
		VH	P1AI0084	D1AD3421	D1AC4022	D1AK7032
T84.66v	Dotam	VL	P1AJ6059	D1AM8341	D1AS9437	D1AS9439
		VH	P1AJ6062	D1AM8341	D1AN8651	D1AS9435

Fig. 13B



Target Binder	Effector		Protein	LC	HC-VH	HC-VL
CH1A1A	Dotam	VL	P1AI0034	D1AD3421	D1AK6974	D1AK6882
		VH	P1AI1622	D1AD3421	D1AH1088	D1AK6959
T84.66v	Dotam	VL	P1AJ6063	D1AM8341	D1AS9441	D1AS9439
		VH	P1AJ6064	D1AM8341	D1AS9447	D1AS9449

(57) Abstract: The present invention relates to novel antibodies which bind to antigens on target cells, such as tumor cells, and which target radionuclides to said cells, to uses of those antibodies as well as methods of making them.

[Continued on next page]

WO 2025/176614 A1

DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— *with international search report (Art. 21(3))*
— *with sequence listing part of description (Rule 5.2(a))*
— *in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE*